Condition: Non Small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060) | Little Rock, Arkansas, United States | Recruiting |
| Highlands Oncology Group-Research Department ( Site 0062) | Springdale, Arkansas, United States | Recruiting |
| Beverly Hills Cancer Center ( Site 0070) | Beverly Hills, California, United States | Recruiting |
| The Angeles Clinic and Research Institute ( Site 0040) | Los Angeles, California, United States | Completed |
| The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079) | Los Angeles, California, United States | Completed |
| UCLA Clinical & Translational Research Center (CTRC) ( Site 0033) | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian ( Site 0096) | Newport Beach, California, United States | Recruiting |
| St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002) | Orange, California, United States | Recruiting |
| San Francisco Oncology Associates ( Site 0066) | San Francisco, California, United States | Recruiting |
| Stamford Hospital ( Site 0083) | Stamford, Connecticut, United States | Recruiting |
| Mayo Clinic in Florida ( Site 0014) | Jacksonville, Florida, United States | Recruiting |
| Mount Sinai Cancer Center ( Site 0038) | Miami Beach, Florida, United States | Recruiting |
+ 255 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06312137